📋 Key Information Summary
- Rheumatoid vasculitis (RV) is a rare, serious extra-articular complication of long-standing seropositive rheumatoid arthritis, occurring in approximately 1–5% of patients with RA.
- Key risk factors include long disease duration (>10 years), high-titre rheumatoid factor (RF) and/or anti-CCP antibodies, male sex, smoking history, persistent joint erosions, and prior nodulosis.
- Cutaneous manifestations are the most common presentation — nailfold infarcts, digital ulceration, palpable purpura, and livedo reticularis — and should prompt urgent vasculitis workup.
- Mononeuritis multiplex (acute onset of foot-drop, wrist-drop, or sensory loss in multiple nerve territories) is a hallmark of moderate-to-severe RV and indicates ischaemic nerve damage.
- Visceral involvement can affect the mesenteric circulation (acute abdomen), coronary arteries (MI), pulmonary parenchyma, and kidneys (necrotising glomerulonephritis), with high morbidity and mortality.
- Diagnosis requires tissue biopsy (skin, sural nerve) demonstrating necrotising or leucocytoclastic vasculitis of small-to-medium vessels; ANCA should be checked to exclude ANCA-associated vasculitis.
- Severity is stratified into limited (cutaneous-only) vs. severe (mononeuritis multiplex, visceral, scleritis) — severe disease demands aggressive immunosuppression.
- Limited skin-only RV: optimise DMARDs, add short course of oral prednisolone 0.5 mg/kg/day tapering over 4–8 weeks.
- Severe RV (nerve, eye, visceral): IV methylprednisolone 500 mg–1 g daily × 3 days then oral taper, PLUS rituximab 1000 mg IV × 2 (days 1 and 15) — first-line per RAVE/EUVAS evidence; cyclophosphamide is second-line.
- Intravenous immunoglobulin (IVIg) 2 g/kg over 2–5 days may be used adjunctively or when infection precludes further immunosuppression.
- RV carries significant mortality (5-year mortality 30–50% for severe multisystem disease); early recognition and aggressive treatment improve outcomes.
- PJP prophylaxis with trimethoprim/sulfamethoxazole is mandatory for patients receiving intensive immunosuppression (rituximab + high-dose corticosteroids or cyclophosphamide).
- Aboriginal and Torres Strait Islander patients may present later with more advanced disease due to healthcare access barriers; culturally safe outreach vasculitis screening should be integrated into chronic disease programmes.
- All patients should be managed in conjunction with rheumatology and, for visceral or neurological involvement, a vasculitis or combined rheumatology–immunology centre of expertise.
Introduction & Australian Epidemiology
Rheumatoid vasculitis (RV) is a necrotising vasculitis affecting small and medium-sized arteries that occurs as an extra-articular manifestation of rheumatoid arthritis (RA). It is distinct from other ANCA-associated vasculitides and represents the most severe extra-articular complication of RA, carrying substantial morbidity and mortality.
The prevalence of RV has declined significantly since the introduction of early aggressive DMARD therapy and biologic agents for RA. Historical series reported 1–5% of RA patients; contemporary Australian data suggest an incidence below 0.5% in patients on modern treat-to-target regimens. However, RV remains an important diagnosis to recognise because of its devastating complications when untreated.
In Australia, RV is managed primarily by rheumatologists with access to vasculitis expertise at tertiary centres (e.g., Royal Adelaide Hospital Vasculitis Clinic, Royal Melbourne Hospital, St Vincent's Sydney, Royal Perth Hospital). Referral to a multidisciplinary vasculitis team is strongly recommended for all patients with suspected severe or systemic RV.
Declining but still deadly: Although less common in the biologic era, RV continues to carry a 5-year mortality of 30–50% for multisystem disease. Delayed diagnosis is the single greatest modifiable risk factor for poor outcomes.
Risk Factors in Long-Standing RA
Rheumatoid vasculitis develops almost exclusively in patients with established, seropositive, erosive RA. The following risk factors have been consistently identified in cohort studies:
| Risk Factor | Detail | Evidence Strength |
|---|---|---|
| Disease duration | Typically >10 years; median 15–20 years at presentation | Strong |
| Seropositivity | High-titre RF (>3× ULN); anti-CCP positivity adds independent risk | Strong |
| Rheumatoid nodulosis | Subcutaneous nodules present in 80–90% of RV patients | Strong |
| Male sex | Male-to-female ratio approximately 1.5–2:1 in RV (cf. 3:1 F:M in RA overall) | Moderate |
| Smoking | Current or ex-smoking doubles risk; dose-dependent relationship | Strong |
| Erosive disease | Radiographic erosions present in virtually all RV patients | Strong |
| Previous extra-articular features | Prior episcleritis, pleuritis, Felty syndrome increase risk | Moderate |
| HLA-DRB1 shared epitope | Homozygosity for shared epitope alleles associated with severe extra-articular RA | Moderate |
| Drug factors | Methotrexate withdrawal or dose reduction may unmask latent vasculitis in some cases | Limited |
Clinical pearl: Patients with long-standing seropositive, nodular RA who develop new skin lesions, neuropathy, or constitutional symptoms should be assessed urgently for vasculitis. The combination of high-titre RF + nodulosis + >10 years disease duration places patients at highest risk.
Cutaneous Manifestations
Skin involvement is the most common presentation of RV, occurring in 80–90% of cases. Cutaneous RV exists on a spectrum from limited (skin-only) to a harbinger of systemic disease.
Nailfold Infarcts (Splinter Haemorrhages)
Small, dark, linear haemorrhages in the nail bed representing distal digital arteriolar occlusion. While common in active RA without vasculitis, the presence of multiple new, painful nailfold infarcts — especially with perungual erythema — raises concern for vasculitis.
Digital Ulceration
Punched-out, painful ulcers at the fingertips (over digital pulps) or periungual areas. These result from small-vessel occlusion and are often bilateral. Deep ulcers that extend to bone carry risk of digital gangrene and amputation.
Livedo Reticularis
A violaceous, net-like mottling pattern most visible on the lower extremities and trunk. In the context of RV, livedo indicates medium-vessel involvement and may be associated with a more aggressive disease course and higher likelihood of visceral disease.
Other Cutaneous Features
- Palpable purpura: Leucocytoclastic vasculitis on histopathology; most common histological finding in RV skin biopsies.
- Deep dermal nodules: Tender nodules on extensor surfaces mimicking rheumatoid nodules but with vasculitic histopathology.
- Pyoderma gangrenosum-like ulceration: Large, undermined, necrotic ulcers — a severe cutaneous manifestation.
- Leg ulceration: Often multifactorial (venous + vasculitic); biopsy essential to distinguish.
Skin = sentinel sign: In 50% of patients with systemic RV, cutaneous lesions precede or coincide with nerve, eye, or visceral involvement. Any new vasculitic skin lesion in a patient with RA warrants full systemic workup.
Mononeuritis Multiplex
Mononeuritis multiplex (MNM) is a hallmark of moderate-to-severe rheumatoid vasculitis and is present in approximately 30–40% of patients with systemic RV. It results from ischaemic damage to the vasa nervorum of peripheral nerves.
Clinical Features
- Acute onset (hours to days) of asymmetric motor and/or sensory deficits in the distribution of two or more named peripheral nerves.
- Common patterns: Foot-drop (common peroneal nerve), wrist-drop (radial nerve), sensory loss in superficial peroneal or sural nerve territories.
- Often preceded by severe neuropathic pain in the affected limb.
- May progress to polyneuropathy if untreated — confluent mononeuritis multiplex mimicking distal symmetric polyneuropathy.
Investigations
- Nerve conduction studies (NCS) / electromyography (EMG): Confirm axonal pattern mononeuritis multiplex (reduced CMAP/SNAP amplitudes with preserved conduction velocities). MBS item 12300 (nerve conduction studies).
- Sural nerve biopsy: Gold standard — demonstrates necrotising arteritis of the vasa nervorum with fibrinoid necrosis. Reserve for diagnostic uncertainty or when skin biopsy is non-diagnostic.
- Exclude mimics: Diabetic mononeuropathy, compressive neuropathies, vasculitis from other aetiologies (PAN, EGPA).
Neurological emergency: Mononeuritis multiplex in the setting of RA is a severe manifestation requiring immediate high-dose immunosuppression (pulse methylprednisolone + rituximab). Delay allows irreversible axonal loss and permanent neurological deficit.
Visceral Involvement
Visceral involvement in RV is less common than cutaneous or neurological disease but carries the highest mortality. Any organ system supplied by small-to-medium arteries can be affected.
| Organ System | Manifestation | Frequency | Key Investigations |
|---|---|---|---|
| Mesenteric / GI | Bowel ischaemia, perforation, acute abdomen | 5–10% | CT angiography abdomen/pelvis; surgical consultation |
| Coronary | Vasculitic coronary arteritis → myocardial infarction | Rare | ECG, troponin, coronary angiography |
| Pulmonary | Parenchymal vasculitis, pulmonary haemorrhage, cavitating nodules | 5–10% | HRCT chest, bronchoscopy with BAL (haemosiderin-laden macrophages) |
| Renal | Necrotising glomerulonephritis (pauci-immune pattern) | 5–15% | Urinalysis, serum creatinine, renal biopsy |
| Ocular | Scleritis (necrotising), peripheral ulcerative keratitis (PUK) | 10–15% | Slit-lamp examination by ophthalmology; urgent referral |
| CNS | Cerebral vasculitis (rare), stroke | <5% | MRI brain with MRA, CSF analysis, exclude embolic/thrombotic causes |
Acute abdomen = surgical + rheumatological emergency: Mesenteric vasculitis in RV can mimic surgical conditions but also requires aggressive immunosuppression. CT angiography should be performed urgently. Involvement of both a surgeon and rheumatologist is essential.
Diagnosis & Biopsy
There are no validated classification criteria specific to rheumatoid vasculitis. Diagnosis is based on clinical features of vasculitis in a patient with established RA, after exclusion of other causes. Tissue biopsy confirming vasculitis is highly desirable.
Diagnostic Approach
- Step 1 — Clinical suspicion: New vasculitic-appearing skin lesions, mononeuritis multiplex, scleritis, or visceral ischaemia in a patient with seropositive RA.
- Step 2 — Exclude mimics: ANCA-associated vasculitis (check c-ANCA/PR3, p-ANCA/MPO), cryoglobulinaemia, infective endocarditis, cholesterol emboli, drug-induced vasculitis, polyarteritis nodosa.
- Step 3 — Tissue biopsy: Skin biopsy of active lesion (punch biopsy including subcutaneous fat) is the first-line approach. Sural nerve biopsy if neuropathy present and skin biopsy non-diagnostic.
- Step 4 — Assess extent: Full systemic workup to determine limited vs. severe disease (see Severity Stratification below).
Biopsy Findings in RV
| Biopsy Site | Histopathology | Sensitivity |
|---|---|---|
| Skin (active lesion) | Leucocytoclastic vasculitis of dermal vessels; fibrinoid necrosis; perivascular neutrophilic infiltrate with nuclear dust | 60–80% (palpable purpura highest yield) |
| Sural nerve | Necrotising arteritis of epineural vessels; axonal degeneration | 80–90% when MNM present |
| Kidney | Pauci-immune necrotising crescentic GN (may be ANCA-negative) | Variable |
| GI tract | Transmural necrotising arteritis; mucosal ulceration | Usually surgical specimen |
Laboratory Investigations
Essential
FBC, ESR, CRP, LFTs, renal function, urinalysis
Baseline organ function; CRP/ESR typically elevated in active RV
Essential
RF and anti-CCP (quantitative titres)
High-titre RF (>3× ULN) is characteristic of RV
Essential
ANCA (c-ANCA/PR3, p-ANCA/MPO)
Exclude ANCA-associated vasculitis; ~15% of RV patients may have positive ANCA
Available
Complement levels (C3, C4, CH50)
May be consumed in RV; helps distinguish from cryoglobulinaemia
Available
Cryoglobulins
Exclude cryoglobulinaemic vasculitis (type II/III can overlap with RA)
Available
Serum electrophoresis / immunoglobulins
Polyclonal hypergammaglobulinaemia common in RV
Available
Blood cultures × 3 sets
Exclude infective endocarditis, which can mimic vasculitis
Available
Hepatitis B and C serology
Before rituximab or immunosuppression; HBV requires antiviral prophylaxis
Risk Stratification / Severity Scoring
RV is classified into limited (cutaneous-only) and severe (systemic) disease. This distinction drives therapeutic intensity.
Limited
Cutaneous-only RV
Nailfold infarcts, superficial ulceration, palpable purpura without deep tissue involvement. No nerve, eye, or visceral disease. Constitutional symptoms may be present but mild.
Setting: Outpatient rheumatology management
Moderate
Cutaneous + Mononeuritis Multiplex or Scleritis
Isolated mononeuritis multiplex (limited nerve involvement) or necrotising scleritis/PUK without visceral organ threat.
Setting: Inpatient or day-infusion immunosuppression; ophthalmology co-management
Severe
Visceral / Life-threatening
Mesenteric ischaemia, coronary arteritis, pulmonary haemorrhage, CNS vasculitis, digital gangrene, rapid progressive GN, or severe polyneuropathy.
Setting: ICU / HDU; pulse IV methylprednisolone + rituximab or cyclophosphamide; multidisciplinary team
Empirical Therapy
Treatment of RV is not protocolised in the same way as ANCA-associated vasculitis, but management principles are similar. All severe RV should be managed in conjunction with a vasculitis or specialist rheumatology centre.
Limited (Cutaneous-Only) Disease
Prednisolone
Solone® · Panafcortelone® · Corticosteroid
Adult dose
0.5 mg/kg/day PO (typically 25–40 mg), taper over 4–8 weeks to ≤7.5 mg/day maintenance
Paediatric dose
0.5–1 mg/kg/day PO; taper as per rheumatology guidance
Renal adjustment
No dose adjustment; monitor for fluid retention
PBS status
✔ PBS General Benefit
Concurrently optimise background DMARD therapy (methotrexate, leflunomide, or sulfasalazine). Adding or increasing hydroxychloroquine 200 mg BD may be considered for mild cutaneous disease.
Moderate-to-Severe Systemic Disease — 1st-Line
Methylprednisolone (IV pulse)
Solu-Medrol® · Corticosteroid
Adult dose
500 mg–1 g IV daily × 3 days, then switch to oral prednisolone 1 mg/kg/day tapering over 3–6 months
Renal adjustment
No adjustment; monitor electrolytes and glucose closely
PBS status
✔ PBS General Benefit (inpatient)
Rituximab
MabThera® · Riximyo® · Anti-CD20 monoclonal antibody
Adult dose
1000 mg IV on Day 1 and Day 15 (2-dose induction); may repeat 6-monthly if relapse
Pre-medication
Paracetamol 1 g PO + chlorphenamine 10 mg IV + methylprednisolone 100 mg IV before each infusion
Key monitoring
Immunoglobulin levels (IgG) pre-dose; hepatitis B screening; PJP prophylaxis required
Renal adjustment
No dose adjustment
PBS status
⚡ PBS Authority Required — RA indication or vasculitis under specialist
2nd-Line / Refractory Disease
Cyclophosphamide
Endoxan® · Alkylating agent
Adult dose
IV pulse: 15 mg/kg IV every 2–3 weeks × 6 pulses (Euro-Lupus protocol adapted); OR 2 mg/kg/day PO for 3–6 months
Mesna prophylaxis
Mesna 20% of cyclophosphamide dose IV at 0, 4, and 8 hours post-dose to prevent haemorrhagic cystitis
Renal adjustment
Reduce dose by 25% if eGFR <30 mL/min/1.73 m²; monitor CBC closely
PBS status
✔ PBS General Benefit
Adjunctive Therapy
Intravenous Immunoglobulin (IVIg)
Intragam P® · Privigen® · Immunoglobulin
Adult dose
2 g/kg total dose, divided over 2–5 days; may repeat monthly × 3–6 months
Indication
Adjunct when infection precludes further immunosuppression; refractory skin disease; cryoglobulinaemic overlap
PBS status
⚡ PBS Authority Required — specialist-initiated
Trimethoprim / Sulfamethoxazole (PJP prophylaxis)
Bactrim DS® · TMP-SMX
Adult dose
160/800 mg (1 DS tablet) PO three times weekly or daily; continue for 6 months after last rituximab dose or while on ≥20 mg prednisolone
Alternative if sulpha-allergic
Dapsone 100 mg PO daily OR atovaquone 1500 mg PO daily OR inhaled pentamidine 300 mg monthly
PBS status
✔ PBS General Benefit
Directed / Pathogen-Specific and Mechanism-Specific Therapy
Rituximab has emerged as the preferred B-cell depleting agent for severe RV based on extrapolation from RAVE and RITUXVAS trials in ANCA-associated vasculitis and observational data in RV specifically. Its mechanism — B-cell depletion reducing RF-producing and autoantibody-producing B lymphocytes — is well-suited to the pathophysiology of RV.
Therapy by Disease Severity
Limited (skin only)
Prednisolone 0.5 mg/kg + DMARD optimisation
Taper over 4–8 weeks
Moderate (MNM / scleritis)
IV methylprednisolone pulse → oral taper + Rituximab 1 g × 2
Induction over 2 weeks; maintenance rituximab 6-monthly if relapse
Severe (visceral / life-threatening)
IV methylprednisolone 1 g × 3 + Rituximab or Cyclophosphamide
Intensive induction 3–6 months; switch to azathioprine or rituximab maintenance
Refractory to rituximab
Cyclophosphamide IV pulse + IVIg 2 g/kg
3–6 month CYC induction; long-term rituximab or azathioprine maintenance
Maintenance Therapy After Induction
- Rituximab maintenance: 500–1000 mg IV every 6 months for a minimum of 2 years, guided by relapse risk. Monitor CD19+ B-cell count and immunoglobulin levels.
- Azathioprine alternative: 2 mg/kg/day PO (check TPMT/NUDT15 genotype before commencing) as maintenance if rituximab not tolerated or unavailable.
- Mycophenolate mofetil: 1–1.5 g BD PO — may be used as steroid-sparing agent in maintenance; limited evidence in RV specifically.
- Methotrexate: Continue background MTX for RA disease control; may be continued through rituximab therapy at reduced dose.
TPMT/NUDT15 screening: Before commencing azathioprine, check thiopurine methyltransferase (TPMT) and NUDT15 genotype (MBS item 73313). Patients who are homozygous deficient are at risk of severe myelosuppression. Intermediate metabolisers require 50–75% dose reduction.
Monitoring
RV requires close monitoring during both induction and maintenance phases, for disease activity, treatment toxicity, and infection risk.
Weeks 0–2
Baseline: FBC, CRP, ESR, LFTs, renal function, hepatitis B/C serology, quantitative immunoglobulins, ANCA, cryoglobulins. Start induction therapy. Assess skin lesions, nerve function (NCS if MNM), ophthalmology review if scleritis.
Weeks 2–6
FBC weekly if on cyclophosphamide; fortnightly if on rituximab. Monitor for infusion reactions. Assess treatment response — healing of ulcers, improvement in neuropathic pain. Check B-cell (CD19+) depletion at 4 weeks post-rituximab.
Months 3–6
Review disease activity. Repeat CRP/ESR. Neurological reassessment (repeat NCS at 3 months if MNM). Immunoglobulin levels — if IgG <4 g/L, withhold rituximab and consider IVIg supplementation. Bone density if >3 months corticosteroids (DEXA).
6–12 months
Decision on maintenance therapy. Repeat ANCA if initially positive. Annual flu vaccine + pneumococcal vaccine (Prevenar 13 then Pneumovax 23). COVID-19 boosters per ATAGI schedule.
Ongoing (annual)
RA disease activity (DAS28). Cardiovascular risk assessment (RV increases CV mortality). Skin surveillance for new lesions. Renal function and urinalysis. Cancer screening (immunosuppression risk). Osteoporosis management.
Vaccination timing: Administer all live vaccines ≥4 weeks before rituximab. Killed/inactivated vaccines should be given ≥2 weeks before rituximab or at least 6 months after the last dose. Live vaccines are contraindicated while B-cells are depleted.
Special Populations
Pregnancy
Corticosteroids
Prednisolone is relatively safe in pregnancy; doses >20 mg/day associated with pre-eclampsia and GDM risk. Dexamethasone and betamethasone cross the placenta — avoid unless preterm labour.
Rituximab
Contraindicated in pregnancy (Category C). B-cell depletion in neonate if given in 2nd/3rd trimester. Adequate contraception required; washout 6–12 months before conception. If pregnancy occurs, withhold further doses.
Cyclophosphamide
Teratogenic — absolutely contraindicated in pregnancy. Adequate contraception essential during and for 3 months after therapy.
Azathioprine
Considered safe in pregnancy for maintenance. Continue at stable dose. TPMT-deficient patients at higher risk of myelosuppression.
Hydroxychloroquine
Safe in pregnancy; recommended to continue throughout — reduces RA flares and may be protective against congenital heart block in anti-Ro/La positive patients.
Paediatrics
General
RV is exceptionally rare in the paediatric population. When vasculitis occurs in juvenile idiopathic arthritis (JIA), it is usually a different entity. Management should be at a tertiary paediatric rheumatology centre.
Rituximab
375 mg/m² IV weekly × 4 doses (lymphoma protocol) or 750 mg/m² × 2 doses (adapted from adult data). PBS Authority may be required for off-label paediatric use.
Elderly
Corticosteroids
Higher risk of steroid-related complications: osteoporosis (start bone protection — alendronate + calcium/vitamin D from outset), diabetes, infections, cataracts. Aim to taper to ≤7.5 mg prednisolone within 3 months.
Rituximab
Generally well tolerated in elderly. Monitor immunoglobulin levels closely — elderly patients are more susceptible to hypogammaglobulinaemia and recurrent infections on repeated cycles.
Cyclophosphamide
Increased risk of myelosuppression and haemorrhagic cystitis. Use IV pulse (lower cumulative dose) rather than daily oral. Consider dose reduction for eGFR <60.
Renal Impairment
Rituximab
No dose adjustment required. Safe in dialysis patients. Monitor for tumour lysis in high-burden disease.
Cyclophosphamide
Reduce dose by 25% if eGFR 15–30 mL/min; by 50% if eGFR <15. Increase monitoring frequency.
Azathioprine
No specific renal adjustment, but dose based on body weight and TPMT status. Monitor FBC more frequently in CKD.
Methotrexate
Contraindicated if eGFR <30 mL/min/1.73 m². Reduce dose and increase monitoring if eGFR 30–50.
Hepatic Impairment
Rituximab
No dose adjustment. Hepatitis B surface antigen positive patients require antiviral prophylaxis (entecavir or tenofovir) starting ≥2 weeks before rituximab and continuing for ≥12 months after last dose.
Methotrexate
Contraindicated in significant hepatic impairment (Child-Pugh B or C). Monitor LFTs fortnightly during active therapy.
Azathioprine
Use with caution — hepatotoxicity risk. Prefer mycophenolate mofetil in patients with liver disease.
Immunocompromised
Infection risk
RV patients on rituximab + corticosteroids have high rates of serious infection (opportunistic infection rate 10–20% in series). Screen for latent TB (IGRA), hepatitis B/C, HIV before starting immunosuppression.
PJP prophylaxis
Mandatory for all patients receiving rituximab + high-dose corticosteroids or cyclophosphamide. TMP-SMX 160/800 mg three times weekly.
Immunoglobulin monitoring
Check IgG, IgA, IgM before each rituximab cycle. If IgG <4 g/L, consider IVIg supplementation and defer further rituximab.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
📚 References
- 1. Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;27(1):63–70.
- 2. Puechal X, et al. Rheumatoid vasculitis: a systematic review of the literature. Autoimmun Rev. 2021;20(5):102800.
- 3. Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis (RAVE). N Engl J Med. 2010;363(3):221–232.
- 4. Jones RB, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis (RITUXVAS). N Engl J Med. 2010;363(3):211–220.
- 5. Bartels CM, et al. Rheumatoid vasculitis: declining incidence in the biologic era. J Rheumatol. 2019;46(6):576–583.
- 6. Sayarlioglu M. Rheumatoid nodules and rheumatoid vasculitis. Turk J Rheumatol. 2014;29(2):121–128.
- 7. Australian Institute of Health and Welfare (AIHW). Rheumatoid arthritis in Aboriginal and Torres Strait Islander peoples. Cat. no. PHE 257. Canberra: AIHW; 2021.
- 8. The Royal Australian College of General Practitioners (RACGP). Smoking, health and Australian policy. East Melbourne: RACGP; 2023.
- 9. National Health and Medical Research Council (NHMRC). Australian guidelines for the clinical care of people with rheumatoid arthritis. Canberra: NHMRC; 2018.
- 10. Chung SA, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Care Res. 2021;73(8):1061–1070.
- 11. RHDAustralia. Australian rheumatic fever and rheumatic heart disease guidelines. 3rd ed. Darwin: Menzies School of Health Research; 2020.
- 12. Mocanu M, et al. Mononeuritis multiplex in rheumatoid vasculitis: outcomes with rituximab therapy. J Clin Rheumatol. 2020;26(4):148–153.
- 13. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024.
- 14. Medical Benefits Schedule (MBS) Online. Australian Government Department of Health. Available at: www.mbsonline.gov.au. Accessed 2024.